Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

Related Keywords

Massachusetts ,United States ,Boston ,Dana Farber Cancer Institute ,Colombo ,Western ,Sri Lanka ,American ,Joycef Liu , ,End Results Program ,Zentalis Pharmaceuticals ,Astrazeneca ,Women Health ,Harvard Medical School ,Division Of Gynecologic Oncology ,American Society Of Clinical Oncology Annual Meeting ,National Cancer Institute Surveillance ,Gynecologic Oncology ,Displays Preliminary Efficacy ,Clinical Oncology Annual Meeting ,Gynecologic Oncology Annual Meeting ,Cancer Institute Surveillance ,End Results ,Accessed May ,Intj Mol ,